Clinical medicine profile
Nebivolol
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC.
Precautions
- Deterioration of renal function, allergic reactions, bradycardia, chest pain, dizziness, dyspnea, edema, hypotension, weight increase, syncope, fever, haematuria, hepatic injury, depression, mental, thrombocytopenia.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Therapeutic use is agent- and indication-specific within the class (Therapeutic agent (verify pharmacological class)).
- Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
- Hypertension, CHF
Adverse effects
- Bradycardia
- headache
- dizziness
- insomnia
- hypercholesterolaemia
- lowered HDL levels
- hyperuricaemia
- raised triglyceride levels
- diarrhoea
- abdominal pain
- thrombocytopenia
- paraesthesia.
Drug interactions
Open multi-drug checker ↗- Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
- Document allergy status and key interactions.
Mechanism & disposition
A non-cardioselective beta-blocker.
Read complete mechanism
A non-cardioselective beta-blocker. It has some vasodilating properties possibly due to its blocking activity of alpha1 receptors e.g carvedilol. Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| Byscard Tablets 2.5mg | THE SEARLE COMPANY LIMITED | Tablet 2.5mg | Unavailable |
| Byscard Tablets 5mg | THE SEARLE COMPANY LIMITED | Tablet 5mg | Unavailable |
| Byscard Tablets 10mg | THE SEARLE COMPANY LIMITED | Tablet 10mg | Unavailable |
| Drugs acting on cardiovascular system | Afya Index / Retail Reference | tabs 40mg 10x10's | KES 800.00afya_index_book |
| Drugs acting on cardiovascular system | Afya Index product / manufacturer unverified | tabs 1mg 250's | Unavailable |
| NEBICARD | DAIMA BIASHARA / Wholesale Import | 5MG * 30`S | KES 1,343.75Daima Chemist price-list reference ↗ Source date not recorded · verify current price |
| NEBIGOOD 5 | ZAIN PHARMA LIMITED | Tablet | Unavailable |
| NEBILET TABLETS | Not recorded | 5MG * 28`S | KES 1,871.87Daima Chemist price-list reference ↗ Source date not recorded · verify current price |
| NEBILONG | DAIMA BIASHARA / Wholesale Import | 10MG TABS 30S | KES 1,096.50Daima Chemist price-list reference ↗ Source date not recorded · verify current price |
| NEBILONG AM TABS 3*10*S | Not recorded | — | UnavailableDaima Chemist price-list reference |
| NEBILONG H TABS *30`S | Not recorded | — | KES 1,385.14Daima Chemist price-list reference ↗ Source date not recorded · verify current price |
| NEBIVAS- 2.5 TABLETS | Innocia Lifesciences Pvt. Ltd. | Tablet | Unavailable |
| NEBIVAS 5 TABLETS | M/s. Innocia Lifesciences Pvt. Ltd. | Tablet | Unavailable |
| NEBIVAS 10 TABLETS | M/s. Innocia Lifesciences Pvt. Ltd. | Tablet | Unavailable |
| NEBTAS 5mg | Intas Pharmaceuticals Ltd | Tablet 5mg | Unavailable |
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.